Absci Corporation (ABSI) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-11
(Q2 2026)
— full calendar
Earnings Reports
-
Abcide (ABSI) Q1 2026: $25B AGA TAM Targeted as ABS-201 Pipeline Expands Beyond Hair Loss
May 08, 2026
-
Absci (ABSI) Q4 2025: ABS-201 Addresses $25B AGA Market as Phase 1-2A Safety Holds
March 25, 2026
-
AbSci (ABSI) Q3 2025: $35M Cash Jump Extends Runway as ABS-201 Dual Indication Strategy Takes Center Stage
November 13, 2025
-
Abcide (ABSI) Q2 2025: $64M Capital Raise Extends Runway, Puts ABS-201 on Accelerated Path
August 12, 2025
-
AbSci (ABSI) Q1 2025: ABS-101 Enters Clinic, Unlocking First-in-Human Milestone
July 06, 2025
-
AbSci (ABSI) Q3 2024: $247M AstraZeneca Milestone Validates AI Platform, Internal Pipeline Targets H1 2025 Data
November 12, 2024
-
AbSci (ABSI) Q2 2024: MSK Partnership Adds Six Programs, Diversifies R&D Model
August 14, 2024
-
AbSci (ABSI) Q1 2024: $86M Raise Extends Runway, Accelerates Internal Pipeline Execution
May 14, 2024